Neurophysiological RCT of Qigong in Elderly With Depression

Sponsor
The Hong Kong Polytechnic University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05000788
Collaborator
(none)
60
1
2
22.7
2.6

Study Details

Study Description

Brief Summary

Summary of Project:

Elderly depression is a common mood disorder and the individuals will have persistent low mood and self-absorption that adversely affect their quality of life. Cognitive deficits including attention and executive function are commonly seen in elderly with depression. Qigong, a mind-body practice, is found to have an anti-depressive effect and improve cognitive functions. Yet, the underlying mechanism is still elusive. Hence, the present study aims to conduct a randomized controlled trial to investigate how the practice of Eight-Section Brocades, a type of qigong, affects the function of the central nervous system in elderly with depression, as measured by fNIRS. A total of 60 elderly (based on power analysis 80% (β= 0.20) chance (α = 0.05, two-tailed)), aged 65 or above, with depressive mood as indicated by the Geriatric Depression Scale (GDS) will be recruited and randomly assigned to the treatment (eight-section brocades) and control (exercise) groups. We anticipate that this ancient Chinese mind-body based practice will result in (1) decreased depressive moods and improved cognitive functions, and (2) acute changes in the functional brain activation patterns in the PFC in elderly with depression. The results of this study will shed light on the neurophysiological underpinnings of the therapeutic effects associated with qigong, which will be invaluable for designing intervention for elderly with depression.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Qigong
  • Behavioral: Exercise
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomized Controlled Neurophysiological Study of Qigong in Elderly With Depression
Actual Study Start Date :
Aug 9, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Qigong Group

Behavioral: Qigong
Eight-Section Brocades Practice: The treatment group will undergo an 8-week Eight-Section Brocades intervention program consists of a total of 16 group training sessions with two 1-hour sessions per week. The treatment group participants will be provided with health qigong exercise in a group format led by qualified qigong instructors. All the health qigong instructors will be trained by a certified Traditional Chinese Medicine (TCM) practitioner with an expertise in health qigong and they are required to pass the certification examination before delivering health qigong intervention at the clinical settings. The Eight-Section Brocades protocol will be used in this study because it is easy to learn by the participants and the clinical effects on psychosocial health were evidenced in previous RCTs. A complete cycle of the Eight-Section Brocades took 12 minutes for completion, which consists of eight sequential and simple forms of movements.
Other Names:
  • Baduanjin
  • Active Comparator: Exercise Group

    Behavioral: Exercise
    Exercise Program: Participants in the control group will attend a physical exercise program for 8 weeks (1-hour sessions, 2 times a week). The exercise program will incorporate aerobic fitness, strength training, body weight workouts, balance training, flexibility and stretching into the training plan. The exercise program is provided in a group format, which will be led by qualified physical trainer.

    Outcome Measures

    Primary Outcome Measures

    1. Change in cognitive function as assessed by Attention Network Test [Changes in time points: Baseline, at the end of the 8 weeks, 1 months after treatment]

      To evaluate the therapeutic effects of qigong on cognitive functions, we assess a range of cognitive functions including attention, inhibition, and executive function: Attention Network Test (ANT). The ANT is a variation from the Flanker test which assesses the efficiency of an individual's subsystems of attention (i.e. alerting, orienting, executive attention). The participants' task is to identify the direction of the central arrow by looking towards the corresponding direction, where either an upward or downward arrow will be presented. The difference of performance between the congruent and incongruent conditions represents inhibitory control ability. Neutral trials will also be presented for measuring simple attention.

    2. Change in cognitive function as assessed by verbal fluency task (VFT) [Changes in time points: Baseline, at the end of the 8 weeks, 1 months after treatment]

      Verbal fluency task (VFT). Executive functions are measured using the VFT. The experimental design of this task is adapted from previous fNIRS studies of verbal fluency where task blocks were interleaved with control blocks. Participants are required to generate exemplars of two semantic categories (i.e., animal and means of transportation) as many as possible, each for one minute, during the task blocks. This experimental task will begin with a 30-second phrase repetition period as a control, followed immediately by a 60-second task period (i.e, animal words), a 60-second control period, another 60-second task period (i.e., transportation words), and ended with another 60-second control period. The total measurement period is 270 seconds. The total number of correct and unique responses will be computed to reflect their fluency ability.

    3. Change in cognitive function as assessed by N-back Task [Changes in time points: Baseline, at the end of the 8 weeks, 1 months after treatment]

      N-back Task. The N-back paradigm that assesses the updating of working memory is adapted and modified from previous neurophysiological studies that consists of 0-back (i.e., low working memory load), and 2-back (i.e., high working memory load) conditions. Each condition will be presented two times and the tasks will be performed alternately in blocks, separated by a 25-35 seconds rest block during which the participants will be instructed to relax and sit still. The order of the two task blocks will be randomized across participants to avoid order effects, and no condition will be repeated consecutively. Each target (a digit) is presented for 500 milliseconds, followed by an interstimulus interval of 1500 milliseconds. Each task block lasts for 45 seconds, and the total duration of the paradigm is 8 minutes. The accuracy rate and RT of this task will be calculated to reflect the capacity of working memory and processing speed.

    4. Change in executive function as assessed by Cambridge Neuropsychological Test Automated Battery (CANTAB®) [Changes in time points: Baseline, at the end of the 8 weeks, 1 months after treatment]

      The CANTAB, a computerised battery of neuropsychological tests, assesses behavioral changes in executive functioning. A test battery that assesses cognitive safety (Roiser et al. 2016) would be used in this study to tap into some of the key cognitive domains. This battery includes four neuropsychological tests which are the (a) Reaction Time (RTI; assesses processing speed and psychomotor speed), (b) Paired Associates Learning (PAL; assesses visual memory and new learning), (c) Spatial Working Memory (SWM, a measure of strategy as well as working memory errors; executive function) and (d) Rapid Visual Information Processing (RVP; assess sustained attention). Also, an emotion recognition task (ERT) which measures the ability to identify emotions in facial expressions will be added to the cognitive safety battery. Six basic emotions will be covered. The total accuracy rate as well as the subscores for different emotions will be recorded to indicate basic emotion recognition ability.

    5. Hemodynamic changes as assessed by functional near-infrared spectroscopy (fNIRS) [Changes in time points: Baseline, at the end of the 8 weeks, 1 months after treatment]

      fNIRS is a non-invasive neuroimaging procedure used to measure hemodynamic changes, in terms of oxyhemoglobin (HbO), deoxyhemoglobin (HbR) and total hemoglobin (HbT), associated with neuronal activities of the cerebral cortex in response to attending a task within the given period of time. Optical signals will be recorded on a two-wavelength (780 and 850 nm), continuous-wave optical imaging system (NIRSIT; OBELAB Co., Seoul, South Korea). The 48 channels with a 30-mm source-detector separation which cover the entire PFC area will be used in this study. In accordance with the international 10-20 EEG system, the center of the bottom probe row will be placed at the reference point Fpz. Consequently, channel 1 to channel 16 represent the right PFC, channel 17 to channel 32 the medial PFC, and channel 33 to channel 48 the left PFC. In addition, NIRSIT has an embedded gyroscope that enables online removal of motion artifacts.

    Secondary Outcome Measures

    1. Change in mood as assessed by Depression Anxiety Stress Scale-21 (DASS-21) [Changes in time points: Baseline, at the end of the 8 weeks, 1 months after treatment]

      The participants' depressive, anxiety, and stress symptoms were evaluated using the 21-item Depression Anxiety Stress Scale [34]. The minimum possible raw score for the depression, anxiety, and stress subscales is 0, while the maximum possible raw score is 21 with higher scores indicating a greater degree of depression, anxiety, and stress. Raw scores on the DASS-21 will need to be multiplied by 2 to calculate the final score for severity labels (normal, mild, moderate, severe, and extremely severe).

    2. Change in mood as assessed by Beck Depression Inventory-II (BDI-II) [Changes in time points: Baseline, at the end of the 8 weeks, 1 months after treatment]

      Beck Depression Inventory-II (BDI-II). The participants' severity of depression was also measured using the 21-item Chinese version of the Beck Depression Inventory-II, with higher scores indicating a more severe degree of depression. The possible minimum score is 0, while the possible maximum score is 63.

    3. Change in mood as assessed by Personal Well Being Index (PWI) [Changes in time points: Baseline, at the end of the 8 weeks, 1 months after treatment]

      Personal Well Being Index (PWI; Lau et al., 2005). This is an 11-item scale ranging from '0' (extremely dissatisfied) to '10' (extremely satisfied) and used to assess subjective well-being of our participants. The PWI score is the mean of the seven life domains. The study conducted by Lau et al. (2005) showed that it was a reliable measure for use in Hong Kong [36]. The coefficient alpha of PWI was 0.80 and the item-total correlations of PWI ranged between 0.33 and 0.69 for Hong Kong Chinese population.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Elderly aged 65 years or above with depressive symptoms as indicated by the Geriatric Depression Scale (GDS).
    Exclusion Criteria:
    • Current positive history of head injury, seizure, stroke, other CNS diseases, other comorbid psychiatric illness, or reports of strong suicidal ideation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Buddhist Ho L.F. Tak Elderly Social Centre North Point HK Island Hong Kong

    Sponsors and Collaborators

    • The Hong Kong Polytechnic University

    Investigators

    • Study Chair: Hector Tsang, PhD, The Hong Kong Polytechnic University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr Yvonne Han, Associate Professor, The Hong Kong Polytechnic University
    ClinicalTrials.gov Identifier:
    NCT05000788
    Other Study ID Numbers:
    • HSEARS20210611001
    First Posted:
    Aug 11, 2021
    Last Update Posted:
    Jan 10, 2022
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr Yvonne Han, Associate Professor, The Hong Kong Polytechnic University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 10, 2022